Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Toripalimab in Acral Lentiginous Malignant Melanoma: NCT06965231 Clinical Landscape Report 2026
15 October 2026
NCT06965231 clinical landscape for Acral Lentiginous Malignant Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Ipilimumab in Metastatic Soft Tissue Sarcoma: NCT06968988 Clinical Landscape Report 2026
15 October 2026
NCT06968988 clinical landscape for Metastatic Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Talquetamab in Multiple Myeloma: ACTRN12625000438459 Clinical Landscape Report 2026
15 October 2026
ACTRN12625000438459 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in HR-positive/HER2-low Breast Carcinoma: NCT06966700 Clinical Landscape Report 2026
15 October 2026
NCT06966700 clinical landscape for HR-positive/HER2-low Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Ganciclovir in Cytomegalovirus viremia: NCT06971913 Clinical Landscape Report 2026
15 October 2026
NCT06971913 clinical landscape for Cytomegalovirus viremia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MVR-T3011 in Non-Muscle Invasive Bladder Neoplasms: NCT06971614 Clinical Landscape Report 2026
15 October 2026
NCT06971614 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Revlucabtagene Autoleucel in Relapse multiple myeloma: NCT06971380 Clinical Landscape Report 2026
15 October 2026
NCT06971380 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ruxolitinib in Acute Myeloid Leukemia: NCT06973668 Clinical Landscape Report 2026
15 October 2026
NCT06973668 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
UTAA-91 in Idiopathic Inflammatory Myopathies: NCT06970951 Clinical Landscape Report 2026
15 October 2026
NCT06970951 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
MOMA-341 in Metastatic Solid Tumor: NCT06974110 Clinical Landscape Report 2026
15 October 2026
NCT06974110 clinical landscape for Metastatic Solid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gemcitabine Hydrochloride in Non-Muscle Invasive Bladder Neoplasms: NCT06972615 Clinical Landscape Report 2026
15 October 2026
NCT06972615 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
RN1101 in Multiple Myeloma: NCT06976437 Clinical Landscape Report 2026
15 October 2026
NCT06976437 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.